title: [Effects of p38MAPK inhibitor on the occurrence of acute GVHD and intestine damage after allogeneic hematopoietic stem cell transplantation in mice].
abstract: OBJECTIVE
  To explore the effects of p38MAPK inhibitor SB203580 (SB) on the occurrence of acute GVHD and intestine damage after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in mice.
  
  
  METHODS
  Sixty BALB/c mice, as recipients, were randomized to control group, irradiation group, model group and intervention group. C57BL/6 mice, as donors, were raised to prepare the bone marrow cells (BMCs) and spleen cells (SCs), which were injected into irradiated recipients mice by tail vein. Except control group, other groups accepted 7.5Gy total body irradiation. Model group and intervention group were infused with BMCs 5×10⁶ and SCs 5×10⁵ by less than 4 h after irradiation. SB was injected into intervention group by intraperitoneally, but only DMSO for model group. The general status and survival rate of each group were evaluated. The expression of p-p38MAPK, Fas and FasL in intestine were determined by RT-PCR, Western blot and immunohistochemistry (IHC).
  
  
  RESULTS
  The weight changes of intervention group (13.00±0.50)% was significantly lighter than that of model group (25.00±0.75)% (P<0.05). The clinical score of acute GVHD in the intervention group (3.33±0.82) was significantly lower than that of model group (6.33±1.36) (P<0.05). The expression levels of p-p38MAPK, Fas and FasL in small intestine of intervention group (1.43±0.02, 0.81±0.03, 0.97±0.03) were lower than those of model group (1.76±0.05, 1.52±0.04, 1.48±0.04).
  
  
  CONCLUSIONS
  SB inhibited the activation of p38MAPK and Fas/ FasL signal pathway and alleviated the apoptosis of small intestine. And SB could relieve small intestine damages induced by allogeneic T lymphocytes.
authors: Department of Pathogenic Biology and Immunology, Xuzhou Medical College, Xuzhou 221002, China.
authors: Cui-ping
authors: CP
authors: Zhang
authors: Xiao-cui
authors: XC
authors: Li
authors: Ren-xian
authors: RX
authors: Tang
authors: Xiang-yang
authors: XY
authors: Li
authors: Kui-yang
authors: KY
authors: Zheng
authors: Ling-yu
authors: LY
authors: Zeng
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D053222:Fas Ligand Protein / Q000378:metabolism; D006086:Graft vs Host Disease / Q000378:metabolism / Q000473:pathology*; D007093:Imidazoles / Q000494:pharmacology*; D007422:Intestines / Q000187:drug effects* / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011725:Pyridines / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects; D014184:Transplantation, Homologous; D019014:fas Receptor / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D053222:Fas Ligand Protein; C491899:Fas protein, mouse; C505658:Fasl protein, mouse; D007093:Imidazoles; D011725:Pyridines; D019014:fas Receptor; D048051:p38 Mitogen-Activated Protein Kinases; C093642:SB 203580